WFH/X
Aug 21, 2025, 14:49
Beyond Factor Therapy: Marstacimab for Hemophilia Care
World Federation of Hemophilia (WFH) shared a post on X:
“Beyond factor therapy: Marstacimab targets TFPI to restore thrombin generation, offering an easier, effective prophylaxis for hemophilia A and B. Strong efficacy and safety in trials. Explore the data.”
Title: Marstacimab for the Treatment of Hemophilia A or B
Author: Johnny Mahlangu
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session